Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management

RESEARCH TRIANGLE PARK, N.C., July 8 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lafmin Morgan has joined the Global Commercial Operations team as vice president, U.S. Product Management.  In this role, Morgan will be responsible for product management and marketing of the company's full product portfolio in the U.S.

"Lafmin brings significant experience and leadership to Talecris and will strengthen our capabilities as we pursue the continued growth of Talecris' U.S. business," said John Perkins, executive vice president, Global Commercial Operations.

Morgan joins Talecris from GlaxoSmithKline (GSK), where he served for more than twenty years in finance, sales, commercial strategy and marketing roles across multiple therapeutic areas. His most recent role at GSK was vice president, Commercial Model Innovations, in which he led GSK's effort to build a new sales and marketing model for the company's entire U.S. business.

Prior to that, Morgan served at GSK as vice president of Sales, a position in which he managed a 2000-person sales force and served as chair of the U.S. Sales Leadership Team. He also served as vice president of Respiratory Marketing, where he implemented a marketing strategy that grew the $5 billion respiratory portfolio by 13 percent in just over one year.  

Morgan holds a Bachelor of Science in Business Administration and a Master of Business Administration from the University of North Carolina at Chapel Hill.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com

SOURCE Talecris Biotherapeutics, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.